{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T11:49:45Z","timestamp":1666266585064},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T00:00:00Z","timestamp":1541980800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s12253-018-0516-3","type":"journal-article","created":{"date-parts":[[2018,11,12]],"date-time":"2018-11-12T06:26:47Z","timestamp":1542004007000},"page":"1497-1503","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Effectiveness of Sorafenib over Other Targeted Agents in the Second-Line Treatment of Metastatic Renal Cell Carcinoma: a Meta-Analysis"],"prefix":"10.1007","volume":"25","author":[{"given":"Hou-Feng","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-Rong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Gang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,12]]},"reference":[{"key":"516_CR1","unstructured":"Eble JN, Sauter G, Epstein JI (2004) Pathology and genetics of tumors of the urinary system and male genital organs. Lyon, France. IARC Press"},{"key":"516_CR2","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G","volume":"28","author":"DG Skinner","year":"1971","unstructured":"Skinner DG, Colvin RB, Vermillion CD, Pfister RC, Leadbetter WF (1971) Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 28:1165\u20131177","journal-title":"Cancer"},{"key":"516_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/SPC.0000000000000277","volume":"11","author":"R Kumar","year":"2017","unstructured":"Kumar R, Kapoor A (2017) Current management of metastatic renal cell carcinoma: evolving new therapies. Curr Opin Support Palliat Care 11:231\u2013237","journal-title":"Curr Opin Support Palliat Care"},{"key":"516_CR4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/j.envpol.2009.02.023","volume":"157","author":"RL Mariani","year":"2009","unstructured":"Mariani RL, Jorge MP, Pereira SS, Melione LP, Carvalho-Oliveira R, Ma TH, Saldiva PH (2009) Association between micronuclei frequency in pollen mother cells of Tradescantia and mortality due to cancer and cardiovascular diseases: a preliminary study in Sao Jose dos Campos, Brazil. Environ Pollut 157:1767\u20131770","journal-title":"Environ Pollut"},{"key":"516_CR5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","volume":"32","author":"TE Hutson","year":"2014","unstructured":"Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB, Senico P, Niethammer A, Lu DR, Hariharan S, Motzer RJ (2014) Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J cElinical Oncol : Off J Am Soc Clin Oncol. 32:760\u2013767","journal-title":"J cElinical Oncol : Off J Am Soc Clin Oncol."},{"key":"516_CR6","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378:1931\u20131939","journal-title":"Lancet"},{"key":"516_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.critrevonc.2016.01.014","volume":"99","author":"R Iacovelli","year":"2016","unstructured":"Iacovelli R, Verri E, Cossu Rocca M, Aurilio G, Cullura D, Santoni M, de Cobelli O, Nole F (2016) Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. Crit Rev Oncol Hematol 99:324\u2013331","journal-title":"Crit Rev Oncol Hematol"},{"key":"516_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114264","volume":"9","author":"DY Heng","year":"2014","unstructured":"Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Qin P, Zhuo DY, Wang X, Park J, Stergiopoulos S, Kollmannsberger C (2014) Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world observational studies. PLoS One 9:e114264","journal-title":"PLoS One"},{"key":"516_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1177\/1756287215612962","volume":"8","author":"LD Borregales","year":"2016","unstructured":"Borregales LD, Adibi M, Thomas AZ, Wood CG, Karam JA (2016) The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol 8:130\u2013141","journal-title":"Ther Adv Urol"},{"key":"516_CR10","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"516_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"516_CR12","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","volume":"14","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S, Oudard S, Gore ME, Tarazi J, Hariharan S, Chen C, Rosbrook B, Kim S, Rini BI (2013) Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14:552\u2013562","journal-title":"Lancet Oncol"},{"key":"516_CR13","first-page":"1363","volume":"8","author":"S Qin","year":"2015","unstructured":"Qin S, Bi F, Jin J, Cheng Y, Guo J, Ren X, Huang Y, Tarazi J, Tang J, Chen C, Kim S, Ye D (2015) Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study. Onco Targets Ther 8:1363\u20131373","journal-title":"Onco Targets Ther"},{"key":"516_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.clinthera.2017.01.017","volume":"39","author":"S Capri","year":"2017","unstructured":"Capri S, Porta C, Delea TE (2017) Cost-effectiveness of Pazopanib versus Sunitinib as first-line treatment for locally advanced or metastatic renal cell carcinoma from an Italian National Health Service Perspective. Clin Ther 39:567\u2013580 e2","journal-title":"Clin Ther"},{"key":"516_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/PPO.0b013e3181bef8cd","volume":"15","author":"J Wilkerson","year":"2009","unstructured":"Wilkerson J, Fojo T (2009) Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer J 15:379\u2013385","journal-title":"Cancer J"},{"key":"516_CR16","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1200\/JCO.2011.38.7571","volume":"30","author":"CM Booth","year":"2012","unstructured":"Booth CM, Eisenhauer EA (2012) Progression-free survival: meaningful or simply measurable? J Clin Oncol : Off J Am Soc Clin Oncol 30:1030\u20131033","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"key":"516_CR17","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.clon.2015.12.004","volume":"28","author":"SK Kang","year":"2016","unstructured":"Kang SK, Volodarskiy A, Ohmann EL, Balar AV, Bangalore S (2016) Efficacy and safety of selective vascular endothelial growth factor receptor inhibitors compared with Sorafenib for metastatic renal cell carcinoma: a meta-analysis of randomised controlled trials. Clin Oncol 28:334\u2013341","journal-title":"Clin Oncol"}],"container-title":["Pathology &amp; Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-018-0516-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-018-0516-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-018-0516-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:16:07Z","timestamp":1573517767000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-018-0516-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,12]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["516"],"URL":"https:\/\/doi.org\/10.1007\/s12253-018-0516-3","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"value":"1219-4956","type":"print"},{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,12]]},"assertion":[{"value":"10 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of Interest"}}]}}